Evotec welcomes Aurélie Dalbiez as Chief People Officer

EQS-News: Evotec SE / Key word(s): Miscellaneous
Evotec welcomes Aurélie Dalbiez as Chief People Officer

17.04.2024 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Hamburg, Germany, 17 April 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809;
NASDAQ: EVO) today announced the appointment of Aurélie Dalbiez as the
Company's new Chief People Officer ('CPO'), effective 15 June 2024. Aurélie
will be joining Evotec's Management Board, bringing with her a wealth of
experience and expertise in Human Resources leadership.

In her role as CPO, Aurélie will oversee the development and implementation
of Evotec's people strategy, focusing on fostering a culture of innovation,
collaboration, and belonging. With over 25 years of international people
leadership experience, Aurélie has a proven track record of driving
organisational transformation and fostering employee engagement.

Prior to joining Evotec, Aurélie served as the Chief Human Resources Officer
('CHRO') at Corbion N.V., a global bio-based ingredients company
headquartered in Amsterdam, Netherlands. During her tenure at Corbion, she
played a key role in shaping Corbion's culture, developing talent, and
leading organisational change.

The creation of a Chief People Officer role in the Management Board
underscores Evotec's commitment to investing in its people and fostering a
supportive and inclusive work environment. Her leadership will be
instrumental in driving Evotec's strategy and empowering employees to reach
their full potential.

Dr Mario Polywka, Chief Executive Officer of Evotec, said: 'We are delighted
to welcome Aurélie to the Evotec team. Her extensive experience and passion
for people development make her the ideal candidate to lead our HR efforts
as we continue to grow our impact in the life sciences industry.'

Aurélie Dalbiez, Evotec's designated Chief People Officer, added: 'I am very
humbled to have been chosen as Evotec's Chief People Officer. I discovered
Evotec as a company with incredibly smart and committed people who are
passionate about the noble work they do every day. I am eager to become part
of the Evotec family and devote my passion to nurturing, developing, and
growing the Evotec talent.'


ABOUT EVOTEC SE
Evotec is a life science company with a unique business model that delivers
on its mission to discover and develop highly effective therapeutics and
make them available to the patients. The Company's multimodality platform
comprises a unique combination of innovative technologies, data and science
for the discovery, development, and production of first-in-class and
best-in-class pharmaceutical products. Evotec leverages this 'Data-driven
R&D Autobahn to Cures' for proprietary projects and within a network of
partners including all Top 20 Pharma and over 800 biotechnology companies,
academic institutions, as well as other healthcare stakeholders. Evotec has
strategic activities in a broad range of currently underserved therapeutic
areas, including e.g. neurology, oncology, as well as metabolic and
infectious diseases. Within these areas of expertise, Evotec aims to create
the world-leading co-owned pipeline for innovative therapeutics and has
to-date established a portfolio of more than 200 proprietary and co-owned
R&D projects from early discovery to clinical development. Evotec operates
globally with more than 5,000 highly qualified people. The Company's 17
sites offer highly synergistic technologies and services and operate as
complementary clusters of excellence. For additional information please go
to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.

FORWARD-LOOKING STATEMENTS
This announcement contains forward-looking statements concerning future
events, including the proposed offering and listing of Evotec's securities.
Words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,'
'intend,' 'may,' 'might,' 'plan,' 'potential,' 'should,' 'target,' 'would'
and variations of such words and similar expressions are intended to
identify forward-looking statements. Such statements include comments
regarding Evotec's expectations for revenues, Group EBITDA and unpartnered
R&D expenses. These forward-looking statements are based on the information
available to, and the expectations and assumptions deemed reasonable by
Evotec at the time these statements were made. No assurance can be given
that such expectations will prove to have been correct. These statements
involve known and unknown risks and are based upon a number of assumptions
and estimates, which are inherently subject to significant uncertainties and
contingencies, many of which are beyond the control of Evotec. Evotec
expressly disclaims any obligations or undertaking to release publicly any
updates or revisions to any forward-looking statements contained herein to
reflect any change in Evotec's expectations with respect thereto or any
change in events, conditions or circumstances on which any statement is
based.

Media Contact Evotec SE:
Gabriele Hansen, SVP Head of Global Corporate Communications,
Gabriele.Hansen@evotec.com
Hinnerk Rohwedder, Director of Global Corporate Communications,
Hinnerk.Rohwedder@evotec.com

IR Contact Evotec SE:
Volker Braun, EVP Head of Global Investor Relations & ESG,
Volker.Braun@evotec.com


---------------------------------------------------------------------------

17.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Evotec SE
                   Manfred Eigen Campus / Essener Bogen 7
                   22419 Hamburg
                   Germany
   Phone:          +49 (0)40 560 81-0
   Fax:            +49 (0)40 560 81-222
   E-mail:         info@evotec.com
   Internet:       www.evotec.com
   ISIN:           DE0005664809
   WKN:            566480
   Indices:        MDAX, TecDAX
   Listed:         Regulated Market in Berlin, Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Dusseldorf, Hamburg,
                   Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq
   EQS News ID:    1881725

End of News EQS News Service
---------------------------------------------------------------------------

1881725 17.04.2024 CET/CEST